Rheumatoid arthritis is the focus of today's Vidyya as the 64th Annual American College of Rheumatology Annual Meeting announces results of studies and research all week as a result of their 64th Annual Meeting.
First in the news, is a landmark study highlighted Sunday during a press conference at the 64th Annual American College of Rheumatology (ACR) Annual Meeting in Philadelphia. The study showed that twice as many patients taking leflunomide experienced significant benefit from the rheumatoid arthritis (RA) therapy, compared to the control group. As a service to our readers, we are providing the prescribing information for leflunomide for you.
Next up, patients with moderately to severely active rheumatoid arthritis experienced sustained reduction of joint pain and swelling for as long as four years of treatment with Enbrel® (etanercept), according to results from a long-term open-label study. In the study, Enbrel continues to be generally well tolerated in patients who have received it for as long as four years. No significant differences in the rate or type of adverse events were seen in these patients treated with Enbrel over time, even though some adverse events have been reported in conjunction with use of the drug. Again, Vidyya has the prescibing information for Enbrel ® for you.
Finally, since rheumatoid arthritis is going to be mentioned in the medical press this week, we are providing a high-quality patient education handout on the disease. This educational handout is for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about this disease. The educational handout describes how rheumatoid arthritis develops, how it is diagnosed, and how it is treated, including what patients can do to help manage their disease.
As always, we hope you enjoy the issue.